PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2009The Journal of Immunology766 citationsOpen Access

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β1

HLHequan LiYHYanmei HanQGQiuli Guo

Key Points

  • To determine how cancer-expanded myeloid-derived suppressor cells regulate natural killer cell innate function and contribute to tumor immune evasion in liver cancer.
  • Assessed hepatic and splenic NK cell function across multiple tumor-bearing mouse models, with detailed focus on an orthotopic liver cancer model.
  • Evaluated NK cell cytotoxicity, NKG2D receptor expression, and IFN-gamma production in vitro and in vivo following co-culture or interaction with MDSCs.
  • Conducted selective in vivo depletion of MDSCs and regulatory T cells to identify the primary mediator of hepatic NK cell impairment.
  • MDSC expansion in the liver and spleen inversely correlated with NK cell function, significantly down-regulating NK cell cytotoxicity, NKG2D expression, and IFN-gamma secretion.
  • Suppression and anergy of NK cells was directly mediated by membrane-bound TGF-beta1 present on MDSCs.
  • Hepatic NK cell function in orthotopic liver cancer-bearing mice was restored by depleting MDSCs, but not by depleting regulatory T cells.

Abstract

NK cells, the important effector of innate immunity, play critical roles in the antitumor immunity. Myeloid-derived suppressor cells (MDSC), a population of CD11b(+)Gr-1(+) myeloid cells expanded dramatically during tumor progression, can inhibit T cells and dendritic cells, contributing to tumor immune escape. However, regulation of NK cell innate function by MDSC in tumor-bearing host needs to be investigated. In this study, we found that the function of NK cells from liver and spleen was impaired significantly in all tumor-bearing models, indicating the impairment of hepatic NK cell function by tumor is a universal phenomenon. Then we prepared the orthotopic liver cancer-bearing mice as tumor model to investigate how hepatic NK cells are impaired. We show that down-regulation of NK cell function is inversely correlated with the marked increase of MDSC in liver and spleen. MDSC inhibit cytotoxicity, NKG2D expression, and IFN-gamma production of NK cells both in vitro and in vivo. After incubation with MDSC, NK cells could not be activated to produce IFN-gamma. Furthermore, membrane-bound TGF-beta1 on MDSC is responsible for MDSC-mediated suppression of NK cells. The impaired function of hepatic NK cells in orthotopic liver cancer-bearing mice could be restored by depletion of MDSC, but not regulatory T cells. Therefore, cancer-expanded MDSC can induce anergy of NK cells via membrane-bound TGF-beta1. MDSC, but not regulatory T cells, are main negative regulator of hepatic NK cell function in tumor-bearing host. Our study provides new mechanistic explanations for tumor immune escape.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2009) studied this question.

synapsesocial.com/papers/69d9a74f7f18ff2fefa3c364https://doi.org/10.4049/jimmunol.182.1.240
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis2024 · 79 citations
  2. 2Abstract B026: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy2025
  3. 3Myeloid-Derived Suppressor Cells in Cancer: Metabolic Reprogramming, Immune Crosstalk, and Therapeutic Targeting2026
  4. 4Natural Killer Cells Reprogram Myeloid-Derived Suppressor Cells to Induce TNF-α Release via NKG2D–Ligand Interaction after Cryo-Thermal Therapy2024 · 2 citations
  5. 5Abstract PR-01: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy2025